Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8650812 | 0.97 | LMNA (0.52) | LMNAKMT2ANPC1MEN1RAB9A | |
| SCHEMBL18528182 | 0.85 | KDM4E (0.47) | LMNAKMT2ANPC1MEN1RAB9A | |
| SCHEMBL8887277 | 0.84 | USP2 (0.52) | LMNAKMT2ANPC1MEN1RAB9A | |
| SCHEMBL18328051 | 0.81 | ALDH1A1 (0.40) | LMNAKMT2ANPC1MEN1RAB9A | |
| SCHEMBL22289985 | 0.78 | MAPT (0.54) | LMNAKMT2ANPC1MEN1RAB9A | |
| SCHEMBL26106785 | 0.77 | HSD17B10 (0.53) | KMT2AMEN1KDM4EMAPTPOLB | |
| SCHEMBL2392492 | 0.74 | KDM4E (0.60) | LMNAKMT2ANPC1MEN1RAB9A | |
| SCHEMBL8643035 | 0.73 | ALDH1A1 (0.49) | LMNAKMT2AMEN1KDM4EMAPT | |
| SCHEMBL6755465 | 0.73 | KMT2A (0.62) | LMNAKMT2ANPC1MEN1RAB9A | |
| SCHEMBL7823939 | 0.73 | LMNA (0.57) | LMNAKMT2ANPC1MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135464-A1 | Antiinflammation agents | AMGEN, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135464-A1 | Antiinflammation agents | AMGEN, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135464-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | LMNA 3720/4885KMT2A 4495/4885NPC1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.